Pop D, Sitar-Taut A, Bodisz G, Zdrenghea D, Cebanu M, Stanca L
University of Medicine & Pharmacy, Department of Internal Medicine; Rehabilitation Hospital,Discipline of Cardiology, Department of Internal Medicine, Cluj-Napoca, Romania.
Babes-Bolyai University, Faculty of Economics & Business Administration, Department of Economic Informatics,, Romania.
Indian J Med Res. 2013 Dec;138(6):866-72.
BACKGROUND & OBJECTIVES: Secretory phospholipase A2 (sPLA2), a member of the phospholipase A2 superfamily of enzymes that hydrolyses phospholipids, is a potentially useful plasma biomarker for atherosclerotic cardiovascular disease. Cardiovascular diseases are the leading cause of mortality in women. The purpose of this study was to investigate the correlation between cardiovascular risk factors and the sPLA2 levels in women with metabolic syndrome as compared to women without metabolic syndrome and men with metabolic syndrome.
Patients (n=100) with various cardiovascular risk factors consecutively evaluated at the Rehabilitation Hospital-Cardiology Department, Cluj-Napoca, Romania were enrolled during 2011, of whom 10 were excluded. The patients were divided in three groups: group 1 (37 women with metabolic syndrome), group 2 (27 men with metabolic syndrome), and group 3 (26 women without metabolic syndrome). Body weight, smoking habits, glycaemia, hypertension, and serum lipids fractions were analysed as cardiovascular factors. Serum sPLA2 activity was measured using the chromogenic method.
There were no statistically significant correlations between sPLA2 levels and the investigated risk factors, irrespective of patient groups. However, there were significant positive correlations between sPLA2 and hsCRP in all three groups (P<0.05). In women with no metabolic syndrome an negative correlation was found between sPLA2 levels and HDL-C- r=-0.419, P=0.03. In men with metabolic syndrome there was a direct correlation between sPLA 2 levels and HOMA, r=0.43, P<0.05, 95% CI (-0.098; 1.15).
INTERPRETATION & CONCLUSIONS: Women with metabolic syndrome did not display different sPLA2 levels as compared to men with metabolic syndrome and women without metabolic syndrome. However, women with metabolic syndrome demonstrated a low but positive correlation between sPLA2 and hsCRP levels.
分泌型磷脂酶A2（sPLA2）是磷脂酶A2超家族中一种能水解磷脂的酶，它可能是动脉粥样硬化性心血管疾病的一种有用的血浆生物标志物。心血管疾病是女性死亡的主要原因。本研究旨在调查与无代谢综合征的女性及有代谢综合征的男性相比，有代谢综合征的女性心血管危险因素与sPLA2水平之间的相关性。
2011年，对罗马尼亚克卢日-纳波卡康复医院心内科连续评估的有各种心血管危险因素的患者（n = 100）进行登记，其中10例被排除。患者分为三组：第1组（37例有代谢综合征的女性）、第2组（27例有代谢综合征的男性）和第3组（26例无代谢综合征的女性）。分析体重、吸烟习惯、血糖、高血压和血脂成分作为心血管因素。采用显色法测定血清sPLA2活性。
无论患者组如何，sPLA2水平与所调查的危险因素之间均无统计学显著相关性。然而，在所有三组中，sPLA2与hsCRP之间均存在显著正相关（P < 0.05）。在无代谢综合征的女性中，sPLA2水平与HDL-C呈负相关 - r = -0.419，P = 0.03。在有代谢综合征的男性中，sPLA2水平与HOMA呈直接相关，r = 0.43，P < 0.05，95% CI（-0.098；1.15）。
与有代谢综合征的男性和无代谢综合征的女性相比，有代谢综合征的女性sPLA2水平没有差异。然而，有代谢综合征的女性sPLA2与hsCRP水平之间显示出低但正相关。
